Maravai LifeSciences (MRVI) stock was downgraded by Baird based on the company's decision to delay its quarterly earnings report and 10-K. Read more here.
Baird downgraded Maravai Lifesciences (MRVI) to Neutral from Outperform with a price target of $3, down from $9, after the company announced ...
Shares of Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences") plunged over 21% in intraday trading on Tuesday, February 25, 2025, after the company disclosed it would be delaying its 2024 ...